Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pe...
Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
About this item
Full title
Author / Creator
Publisher
United States: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: Public Library of Science
Subjects
More information
Scope and Contents
Contents
Oral miltefosine has been shown to be non-inferior to first-line, injectable meglumine antimoniate (MA) for the treatment of cutaneous leishmaniasis (CL) in children. Miltefosine may be administered via in-home caregiver Directly Observed Therapy (cDOT), while patients must travel to clinics to receive MA. We performed a cost-effectiveness analysis...
Alternative Titles
Full title
Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_1899334569
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1899334569
Other Identifiers
ISSN
1935-2735,1935-2727
E-ISSN
1935-2735
DOI
10.1371/journal.pntd.0005459
